Latest Ratios: P/E Ratio -0.9x · EV/EBITDA N/A · ROE -53.9%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $56M | $93M | $231M | $109M | $253M | — | — |
| Enterprise Value | $17M | $54M | $194M | $77M | $228M | — | — |
| P/E Ratio → | -0.88 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 0.61 | 0.82 | 1.30 | 0.90 | 1.48 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -53.9% | -53.9% | -54.1% | -41.4% | -42.5% | — | — |
| ROA | -47.7% | -47.7% | -48.1% | -37.8% | -21.7% | -29.9% | -242.8% |
| ROIC | -58.9% | -58.9% | -58.1% | -42.8% | -174.1% | — | — |
| ROCE | -57.3% | -57.3% | -58.6% | -44.9% | -23.5% | -30.8% | -201.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.04 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | -0.20 | -0.26 | -0.14 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — |
Net cash position: cash ($41M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 7.69 | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 | 2.80 |
| Quick Ratio | 7.69 | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 | 2.80 |
| Cash Ratio | 7.57 | 7.57 | 10.43 | 9.58 | 19.61 | 34.18 | 2.58 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $39M | $38M | $22M | $22M | $13M | $13M |
Clinical trial execution failure
Based on reported figures, ACRV trades at a price-to-book ratio of 0.57, which appears to reflect a significant discount compared to precision oncology peers, suggesting the market is heavily discounting the firm's intangible intellectual property and the long-term commercial viability of its proprietary AP3 proteomic platform.
The current valuation multiple suggests that investors are prioritizing tangible asset backing over the speculative potential of the company's clinical pipeline. This valuation gap relative to peers like Revolution Medicine may indicate that the market is waiting for definitive clinical proof-of-concept before assigning a higher platform premium to the AP3 methodology.
As reported in financial statements, ACRV's ROIC has consistently trended in negative territory, reaching -21.7% in 2026Q1, which highlights the structural challenge of compounding capital in a pre-revenue biotechnology firm where every dollar invested is directed toward non-discretionary clinical trial and diagnostic development costs.
The persistent decay in return on invested capital is a direct consequence of the company's high-burn R&D model, which lacks the offsetting revenue streams necessary to generate positive returns. Investors should monitor whether the upcoming clinical readouts can shift this trajectory by validating the efficacy of ACR-368 and justifying the capital intensity.
According to recent SEC filings, the company's accounts payable turnover has shown extreme volatility, with DPO figures fluctuating wildly between 344 and 2023 days, suggesting that the firm's working capital management is heavily influenced by the irregular timing of clinical trial milestone payments and vendor accruals.
The lack of consistent turnover metrics is typical for a clinical-stage entity, but the extreme DPO swings warrant further investigation into the company's cash management practices. This volatility may imply that the firm is strategically managing its cash outflows to preserve liquidity in anticipation of future capital needs.
As reported in quarterly filings, the company maintains a current ratio of 8.98 as of 2026Q1, which appears to provide a temporary cushion, yet this metric is misleading as it masks the firm's ongoing reliance on external equity financing to sustain its core clinical operations.
While the current ratio suggests a comfortable short-term position, the rapid depletion of cash reserves indicates that the company remains vulnerable to market conditions. The reliance on periodic capital raises, such as the April 2024 PIPE, is essential to maintaining the operational runway required for late-stage clinical execution.
The price-to-book ratio is the most commonly misapplied metric for ACRV, as it fails to capture the value of the company's proprietary AP3 platform and its potential for future licensing, which are not reflected in the firm's minimal tangible asset base or historical accounting figures.
Investors should instead focus on enterprise value relative to R&D spend, as this provides a more accurate reflection of how the market values the company's intellectual property. Relying on P/B in a biotech context risks ignoring the fundamental value of the clinical pipeline and the diagnostic companion technology.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACRV stock.
Acrivon Therapeutics, Inc. Common Stock's current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
Acrivon Therapeutics, Inc. Common Stock's return on equity (ROE) is -53.9%. The historical average is -48.0%.
Based on historical data, Acrivon Therapeutics, Inc. Common Stock is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.